Literature DB >> 8596630

Down's syndrome-like skeletal abnormalities in Ets2 transgenic mice.

S H Sumarsono1, T J Wilson, M J Tymms, D J Venter, C M Corrick, R Kola, M H Lahoud, T S Papas, A Seth, I Kola.   

Abstract

Expression of Ets2, a proto-oncogene and transcription factor, occurs in a variety of cell types. During murine development it is highly expressed in newly forming cartilage, including in the skull precursor cells and vertebral primordia. Ets2 is located on human chromosome 21 (ref. 8) and is overexpressed in Down's syndrome (trisomy 21). Here we generate transgenic mice to investigate the consequences of overexpression of Ets2. We find that mice with less than 2-fold Ets2 overexpression in particular organs develop neurocranial, viscerocranial and cervical skeletal abnormalities. These abnormalities have similarities with the skeletal anomalies found in trisomy-16 mice and humans with Down's syndrome, in which the gene dosage of Ets2 is increased. Our results indicate that Ets2 has a role in skeletal development and implicate the overexpression of Ets2 in the genesis of some skeletal abnormalities that occur in Down's syndrome.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8596630     DOI: 10.1038/379534a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  40 in total

1.  Functional analysis of the transcription factor ER71 and its activation of the matrix metalloproteinase-1 promoter.

Authors:  Luciano De Haro; Ralf Janknecht
Journal:  Nucleic Acids Res       Date:  2002-07-01       Impact factor: 16.971

2.  Overexpression of ETS2 in human esophageal squamous cell carcinoma.

Authors:  Xin Li; Jia-Yun Lu; Li-Qun Zhao; Xiu-Qin Wang; Gui-Lin Liu; Zhong Liu; Chuan-Nong Zhou; Min Wu; Zhi-Hua Liu
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

3.  ETS target genes: identification of egr1 as a target by RNA differential display and whole genome PCR techniques.

Authors:  L Robinson; A Panayiotakis; T S Papas; I Kola; A Seth
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-08       Impact factor: 11.205

4.  Identification of a second promoter in the human c-ets-2 proto-oncogene.

Authors:  A Bègue; P Crepieux; N Vu-Dac; A Hautefeuille; N Spruyt; V Laudet; D Stehelin
Journal:  Gene Expr       Date:  1997

5.  The ETS family member ERM contains an alpha-helical acidic activation domain that contacts TAFII60.

Authors:  P A Defossez; J L Baert; M Monnot; Y de Launoit
Journal:  Nucleic Acids Res       Date:  1997-11-15       Impact factor: 16.971

6.  Physical interactions between Ets and NF-kappaB/NFAT proteins play an important role in their cooperative activation of the human immunodeficiency virus enhancer in T cells.

Authors:  A G Bassuk; R T Anandappa; J M Leiden
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

7.  Analysis of gene networks in white adipose tissue development reveals a role for ETS2 in adipogenesis.

Authors:  Kivanç Birsoy; Ryan Berry; Tim Wang; Ozge Ceyhan; Saeed Tavazoie; Jeffrey M Friedman; Matthew S Rodeheffer
Journal:  Development       Date:  2011-11       Impact factor: 6.868

8.  CDK10/cyclin M is a protein kinase that controls ETS2 degradation and is deficient in STAR syndrome.

Authors:  Vincent J Guen; Carly Gamble; Marc Flajolet; Sheila Unger; Aurélie Thollet; Yoan Ferandin; Andrea Superti-Furga; Pascale A Cohen; Laurent Meijer; Pierre Colas
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-11       Impact factor: 11.205

Review 9.  Overview: engineering transgenic constructs and mice.

Authors:  Naoto Haruyama; Andrew Cho; Ashok B Kulkarni
Journal:  Curr Protoc Cell Biol       Date:  2009-03

10.  Transchromosomic cell model of Down syndrome shows aberrant migration, adhesion and proteome response to extracellular matrix.

Authors:  Frédéric Delom; Emma Burt; Alex Hoischen; Joris Veltman; Jürgen Groet; Finbarr E Cotter; Dean Nizetic
Journal:  Proteome Sci       Date:  2009-08-28       Impact factor: 2.480

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.